Could high-dose-rate monotherapy survive beyond stereotactic ablative radiotherapy era for clinically localized prostate cancer?. (February 2022) - Yamazaki, Hideya; Suzuki, Gen; Aibe, Norihiro; Masui, Koji; Yoshida, Ken; Nakamura, Satoaki